Quantum Group subsidiary received CSR for Phase 1 MAD trial

Quantum BioPharma announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical study report, CSR, for the trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, MAD, Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants.” The CSR concludes that there were no safety or tolerability concerns that were identified in healthy participants following treatment with consecutive daily dosing of Lucid-MS. “We are thrilled that we now have the CSR for the Phase 1 MAD trial and that Lucid-MS was found to be safe and well-tolerated in healthy participants. The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug application with the FDA,” said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma.